Press Releases Cellectis S.A.

Equities

ALCLS

FR0010425595

Real-time Euronext Paris Other stock markets 03:01:21 2024-04-29 am EDT			5-day change	1st Jan Change
2.375 ^EUR	+1.28%		-3.26%	-14.07%

Apr. 26	European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4%	MT
Apr. 25	European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cellectis Presents Novel TALEN Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs	Apr. 23	AQ
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs	Apr. 22	GL
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs	Apr. 10	GL
Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting	Apr. 08	GL
Cellectis S A : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social	Apr. 04	PU
Cellectis S A : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social	Mar. 04	PU
Acute Lymphocytic Leukemia Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024	Feb. 22	AQ
Cellectis announces the drawdown of the second tranche of EUR15 million under the credit facility agreement entered with the European Investment Bank	Jan. 17	AQ
Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)	Jan. 16	GL
Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)	Jan. 16	AQ
Cellectis S A : Vote Results General Shareholders’ Meeting December 22, 2023	Dec. 24	PU
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023	Dec. 22	GL
Cellectis S A : Extraordinary Resolutions - Form 6-K	Dec. 22	PU
Acute Lymphocytic Leukemia Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 (Updated)	Dec. 22	AQ
Cellectis S A : Depositary's Notice of Combined Ordinary and Extraordinary General Meeting of Cellectis S.A - Form 6-K	Dec. 05	PU
Cellectis Shareholders Meeting to be Held on December 22, 2023	Nov. 20	AQ
Cellectis’ Shareholders Meeting to be Held on December 22, 2023	Nov. 17	GL
Cellectis’ Shareholders Meeting to be Held on December 22, 2023	Nov. 17	AQ
Cellectis S A : Document AMF CP. 2023E938653	Nov. 17	PU
Cellectis S A : Document AMF CP. 2023E938388	Nov. 16	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Cellectis S.A.

Equities

ALCLS

FR0010425595

Press Releases

Filters